1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope
2. Executive Summary
2.1. Market Snapshot: U.S. 503b Compounding Pharmacies Market
2.2. U.S. 503b Compounding Pharmacies Market, By Molecule
2.3. U.S. 503b Compounding Pharmacies Market, By Packaging
2.4. U.S. 503b Compounding Pharmacies Market, By Region
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. U.S. 503b Compounding Pharmacies Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Molecule
3.5.2. Packaging
3.5.3. Geography
4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Molecule Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend
5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others
6. Economic Impact Analysis
6.1. Recession Impact
6.2. Ukraine-Russia War Impact
6.3. COVID-19 Impact Analysis
7. U.S. 503b Compounding Pharmacies Market
7.1. U.S. 503b Compounding Pharmacies Market, by Molecule, 2017-2030 (US$ Bn)
7.1.1. Overview
7.1.2. U.S. 503b Compounding Pharmacies Market, By Molecule, 2022 vs 2030 (in%)
7.1.3. U.S. 503b Compounding Pharmacies Market, By Acetaminophen, 2017-2030 (US$ Bn)
7.1.4. U.S. 503b Compounding Pharmacies Market, By Phenylephrine, 2017-2030 (US$ Bn)
7.1.5. U.S. 503b Compounding Pharmacies Market, By Midazolam, 2017-2030 (US$ Bn)
7.1.6. U.S. 503b Compounding Pharmacies Market, By Esmolol, 2017-2030 (US$ Bn)
7.1.7. U.S. 503b Compounding Pharmacies Market, By Vancomycin, 2017-2030 (US$ Bn)
7.1.8. U.S. 503b Compounding Pharmacies Market, By Epinephrine, 2017-2030 (US$ Bn)
7.1.9. U.S. 503b Compounding Pharmacies Market, By Adenocaine, 2017-2030 (US$ Bn)
7.1.10. U.S. 503b Compounding Pharmacies Market, By Fentanyl/ Bupivacaine, 2017-2030 (US$ Bn)
7.1.11. U.S. 503b Compounding Pharmacies Market, By Morphine, 2017-2030 (US$ Bn)
7.1.12. U.S. 503b Compounding Pharmacies Market, By Amiodarone, 2017-2030 (US$ Bn)
7.1.13. U.S. 503b Compounding Pharmacies Market, By Heparin, 2017-2030 (US$ Bn)
7.1.14. U.S. 503b Compounding Pharmacies Market, By Ketamine, 2017-2030 (US$ Bn)
7.1.15. U.S. 503b Compounding Pharmacies Market, By Dextrose, 2017-2030 (US$ Bn)
7.1.16. U.S. 503b Compounding Pharmacies Market, By Hydromorphone, 2017-2030 (US$ Bn)
7.1.17. U.S. 503b Compounding Pharmacies Market, By Bupivacaine, 2017-2030 (US$ Bn)
7.1.18. U.S. 503b Compounding Pharmacies Market, By Lidocaine, 2017-2030 (US$ Bn)
7.1.19. U.S. 503b Compounding Pharmacies Market, By BKK (Bupivacaine, ketorolac, Ketamine), 2017-2030 (US$ Bn)
7.1.20. U.S. 503b Compounding Pharmacies Market, By RCK (Ropivacaine, Clonidine, Ketorolac), 2017-2030 (US$ Bn)
7.1.21. U.S. 503b Compounding Pharmacies Market, By RKK (Ropivacaine, Ketorolac, Ketamine), 2017-2030 (US$ Bn)
7.1.22. U.S. 503b Compounding Pharmacies Market, By Other Molecules, 2017-2030 (US$ Bn)
7.2. U.S. 503b Compounding Pharmacies Market, by Packaging, 2017-2030 (US$ Bn)
7.2.1. Overview
7.2.2. U.S. 503b Compounding Pharmacies Market, By Packaging, 2022 vs 2030 (in%)
7.2.3. U.S. 503b Compounding Pharmacies Market, By Vials, 2017-2030 (US$ Bn)
7.2.4. U.S. 503b Compounding Pharmacies Market, By Prefilled Syringes, 2017-2030 (US$ Bn)
7.2.5. U.S. 503b Compounding Pharmacies Market, By Ampoules, 2017-2030 (US$ Bn)
7.2.6. U.S. 503b Compounding Pharmacies Market, By Syringes, 2017-2030 (US$ Bn)
7.2.7. U.S. 503b Compounding Pharmacies Market, By Others, 2017-2030 (US$ Bn)
7.3. U.S. 503b Compounding Pharmacies Market Estimates and Forecast, 2017-2030 (US$ Bn)
7.3.1. U.S.
7.3.1.1. U.S. 503b Compounding Pharmacies, By Molecule, 2017-2030 (US$ Bn)
7.3.1.2. U.S. 503b Compounding Pharmacies, By Packaging, 2017-2030 (US$ Bn)
8. Company Profiles
8.1. Central Admixture Pharmacy Services, Inc.
8.1.1. Company Overview
8.1.2. Products/Services Portfolio
8.1.3. Geographical Presence
8.1.4. Financial Summary
8.1.4.1. Market Revenue and Net Profit (2019-2022)
8.1.4.2. Business Segment Revenue Analysis
8.1.4.3. Geographical Revenue Analysis
8.2. Nephron Pharmaceuticals Corporation
8.3. QuVa Pharma
8.4. Olympia Pharmacy
8.5. ASP Cares
8.6. Fagron Compounding Pharmacies
8.7. Athenex, Inc.
8.8. Avella Specialty Pharmacy
8.9. Atlas Pharmaceuticals
8.10. Empower Pharmacy
8.11. Carie Boyd’S Prescription Shop
8.12. Edge Pharma, Imprimis NJOF
8.13. IntegraDose Compounding services
8.14. Wells Pharma of Houston, LLC
8.15. US Compounding Inc.
8.16. SCA Pharma
List of Figures
FIG. 1 U.S. 503b Compounding Pharmacies Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 U.S. 503b Compounding Pharmacies Market Segmentation
FIG. 4 U.S. 503b Compounding Pharmacies Market, by Molecule, 2022 (US$ Bn)
FIG. 5 U.S. 503b Compounding Pharmacies Market, by Packaging, 2022 (US$ Bn)
FIG. 6 Attractive Investment Proposition, by Molecule, 2022
FIG. 7 Attractive Investment Proposition, by Packaging, 2022
FIG. 8 Market Share Analysis of Key U.S. 503b Compounding Pharmacies Market Manufacturers, 2022
FIG. 9 Market Positioning of Key U.S. 503b Compounding Pharmacies Market Manufacturers, 2022
FIG. 10 U.S. 503b Compounding Pharmacies Market Value Contribution, By Molecule, 2022 & 2030 (Value %)
FIG. 11 U.S. 503b Compounding Pharmacies Market, by Acetaminophen, Value, 2017-2030 (US$ Bn)
FIG. 12 U.S. 503b Compounding Pharmacies Market, by Phenylephrine, Value, 2017-2030 (US$ Bn)
FIG. 13 U.S. 503b Compounding Pharmacies Market, by Midazolam, Value, 2017-2030 (US$ Bn)
FIG. 14 U.S. 503b Compounding Pharmacies Market, by Esmolol, Value, 2017-2030 (US$ Bn)
FIG. 15 U.S. 503b Compounding Pharmacies Market, by Vancomycin, Value, 2017-2030 (US$ Bn)
FIG. 16 U.S. 503b Compounding Pharmacies Market, by Epinephrine, Value, 2017-2030 (US$ Bn)
FIG. 17 U.S. 503b Compounding Pharmacies Market, by Adenocaine, Value, 2017-2030 (US$ Bn)
FIG. 18 U.S. 503b Compounding Pharmacies Market, by Fentanyl/ Bupivacaine, Value, 2017-2030 (US$ Bn)
FIG. 19 U.S. 503b Compounding Pharmacies Market, by Morphine, Value, 2017-2030 (US$ Bn)
FIG. 20 U.S. 503b Compounding Pharmacies Market, by Amiodarone, Value, 2017-2030 (US$ Bn)
FIG. 21 U.S. 503b Compounding Pharmacies Market, by Heparin, Value, 2017-2030 (US$ Bn)
FIG. 22 U.S. 503b Compounding Pharmacies Market, by Ketamine, Value, 2017-2030 (US$ Bn)
FIG. 23 U.S. 503b Compounding Pharmacies Market, by Dextrose, Value, 2017-2030 (US$ Bn)
FIG. 24 U.S. 503b Compounding Pharmacies Market, by Hydromorphone, Value, 2017-2030 (US$ Bn)
FIG. 25 U.S. 503b Compounding Pharmacies Market, by Bupivacaine, Value, 2017-2030 (US$ Bn)
FIG. 26 U.S. 503b Compounding Pharmacies Market, by Lidocaine, Value, 2017-2030 (US$ Bn)
FIG. 27 U.S. 503b Compounding Pharmacies Market, by BKK (Bupivacaine, ketorolac, Ketamine), Value, 2017-2030 (US$ Bn)
FIG. 28 U.S. 503b Compounding Pharmacies Market, by RCK (Ropivacaine, Clonidine, Ketorolac), Value, 2017-2030 (US$ Bn)
FIG. 29 U.S. 503b Compounding Pharmacies Market, by RKK (Ropivacaine, Ketorolac, Ketamine), Value, 2017-2030 (US$ Bn)
FIG. 30 U.S. 503b Compounding Pharmacies Market, by Other Molecules, Value, 2017-2030 (US$ Bn)
FIG. 31 U.S. 503b Compounding Pharmacies Market Value Contribution, By Packaging, 2022 & 2030 (Value %)
FIG. 32 U.S. 503b Compounding Pharmacies Market, by Vials, Value, 2017-2030 (US$ Bn)
FIG. 33 U.S. 503b Compounding Pharmacies Market, by Prefilled Syringes, 2017-2030 (US$ Bn)
FIG. 34 U.S. 503b Compounding Pharmacies Market, by Ampoules, 2017-2030 (US$ Bn)
FIG. 35 U.S. 503b Compounding Pharmacies Market, by Syringes, 2017-2030 (US$ Bn)
FIG. 36 U.S. 503b Compounding Pharmacies Market, by Others, 2017-2030 (US$ Bn)
List of Tables
TABLE 1 Market Snapshot: U.S. 503b Compounding Pharmacies Market
TABLE 2 U.S. 503b Compounding Pharmacies Market, by Competitive Benchmarking, 2022
TABLE 3 U.S. 503b Compounding Pharmacies Market, by Geographical Presence Analysis, 2022
TABLE 4 U.S. 503b Compounding Pharmacies Market, by Key Strategies Analysis, 2022
TABLE 5 U.S. 503b Compounding Pharmacies Market, by Molecule, 2017-2030 (US$ Bn)
TABLE 6 U.S. 503b Compounding Pharmacies Market, by Packaging, 2017-2030 (US$ Bn)